已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Therapeutic effect of Zhibitai combined with atorvastatin in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of hypersensitive C-reactive protein

医学 阿托伐他汀 高脂血症 内科学 甘油三酯 C反应蛋白 冠心病 胃肠病学 血脂 入射(几何) 不利影响 胆固醇 高密度脂蛋白 冠状动脉疾病 急性冠脉综合征 心脏病学 内分泌学 炎症 心肌梗塞 糖尿病 物理 光学
作者
Tong Lu,Bin Tan,Tingting Deng,Yongping Hua,Gang Xu
出处
期刊:Chinese Journal of Primary Medicine and Pharmacy 卷期号:26 (24): 3022-3025
标识
DOI:10.3760/cma.j.issn.1008-6706.2019.24.020
摘要

Objective To study the effect of atorvastatin combined with Zhibitai in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of high-sensitivity C-reactive protein(hsCRP). Methods A total of 136 patients with coronary heart disease and hyperlipidemia admitted to the Third People's Hospital of Jingdezhen from September 2016 to September 1818 were randomly divided into control group and combination group using stochastic comprehensive balance method, with 68 cases in each group.The control group was treated with atorvastatin and the combination group was treated with lipidine plus atorvastatin. The patient's treatment effect, including the blood lipid compliance rate and the occurrence of adverse reactions during the treatment were observed, as well as the patient's pre-and post-treatment triglyceride(TG), 12h serum total cholesterol(TC), high-density lipoprotein-cholesterol(HDL-C), low density lipoprotein-cholesterol(LDL-C)and high-sensitivity C-reactive protein(hsCRP)and other indicators were measured. Results (1)The blood lipid compliance rate(89.86%) in the combined group was higher than that in the control group(59.70%), the difference was statistically significant(χ2=14.915, P=0.000). (2)The incidence of adverse reactions in the combined group(1.45%) was lower than that in the control group(17.91%), the difference was statistically significant(χ2=8.836, P=0.003). (3)The results showed that the TC, TG, LDL-C, hsCRP and other indicators of the combined group were lower than those of the control group and before treatment, while the HDL-C index of the combined groupwas higher than that of the control group and before treatment, the differences were statistically significant(t=20.800, 4.903, 11.657, 4.346, 6.262, P=0.000, 0.000, 0.000, 0.000, 0.000). Conclusion Zhibitai combined with atorvastatin in the treatment of coronary heart disease patients with hyperlipidemia has remarkable effect.It can accurately control TC, TG, LDL-C, HDL-C and hsCRP, improve blood lipid control rate. Key words: Coronary artery disease; Hyperlipidemias; Lipoproteins, HDL; Cholesterol, LDL; C-Reactive protein; Triglycerides; Adverse reactions; Zhibitai; Atorvastatin

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MiyaGuo发布了新的文献求助10
刚刚
3秒前
森林有鹿完成签到 ,获得积分10
5秒前
jesen发布了新的文献求助30
6秒前
琪凯定理发布了新的文献求助10
8秒前
9秒前
9秒前
CipherSage应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
搜集达人应助科研通管家采纳,获得10
9秒前
共享精神应助科研通管家采纳,获得10
9秒前
李健应助科研通管家采纳,获得10
9秒前
9秒前
华仔应助科研通管家采纳,获得10
10秒前
小马甲应助科研通管家采纳,获得10
10秒前
万能图书馆应助ht采纳,获得10
11秒前
东方元语应助仙林AK47采纳,获得20
11秒前
13秒前
darcy完成签到,获得积分10
13秒前
14秒前
summerway3520发布了新的文献求助10
18秒前
贝林7完成签到,获得积分10
18秒前
时有黄昏完成签到 ,获得积分10
18秒前
TCMning发布了新的文献求助10
18秒前
我是老大应助花小研采纳,获得10
19秒前
研友_nvNz4n关注了科研通微信公众号
20秒前
yu完成签到,获得积分20
22秒前
24秒前
TCMning发布了新的文献求助100
25秒前
26秒前
27秒前
田様应助粉肠粉采纳,获得30
27秒前
28秒前
huang发布了新的文献求助30
29秒前
岂有此李完成签到,获得积分10
30秒前
cdercder应助奶味蓝采纳,获得10
31秒前
CodeCraft应助一亩蔬菜采纳,获得10
32秒前
32秒前
小菲完成签到 ,获得积分10
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
卤化钙钛矿人工突触的研究 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Malcolm Fraser : a biography 700
Handbook of Optical Systems,Volume 6:Advanced Physical Optics 666
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6515122
求助须知:如何正确求助?哪些是违规求助? 8308424
关于积分的说明 17756142
捐赠科研通 5616916
什么是DOI,文献DOI怎么找? 2924847
邀请新用户注册赠送积分活动 1901915
关于科研通互助平台的介绍 1763189